Pharmaceuticals
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the successful release of the first ...
2025-06-20 20:09
2935
The Department of Health - Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi
Reinforcing Abu Dhabi's position as a global life science hub
ABU DHABI, UAE, June 20, 2025 /PRNewswire/ -- During BIO International
Convention in Boston USA, theDepartment of Health – Abu Dhabi
2025-06-20 16:00
2351
The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi
On the sidelines of a high-level US visit focused on healthcare innovation
ABU DHABI, UAE, June 19, 2025 /PRNewswire/ -- The Department of Health – Abu
Dhabi
2025-06-19 16:00
2631
Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, de...
2025-06-19 14:11
2430
LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
* Expanding track record by signing contracts with various global companies across Asia and Europe SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a ...
2025-06-19 07:00
2076
Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the SD-101 Program Globally. MT PLEASANT, S.C.,...
2025-06-18 22:00
2223
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of Myasthenia Gravi...
2025-06-17 23:16
2240
International Pharmaceuticals, Inc. Partners with Anchanto to Power E-commerce Operations in the Philippines
CEBU CITY, Philippines, June 17, 2025 /PRNewswire/ -- Anchanto, the leading global B2B SaaS technology company in e-commerce and supply chain, announced its latest partnership with International Pharmaceuticals, Inc. (IPI), one of Philippines' leading manufacturer and distributor of pharmaceutica...
2025-06-17 11:07
1988
A Decade of Persistent Steps, Aspiring for a Thousand Miles: Qyuns' Grand 10th Anniversary Celebration Held Successfully
TAIZHOU, China, June 16, 2025 /PRNewswire/ -- A Decade of Persistent Steps, Aspiring for a Thousand Miles! From June 13th to 14th, 2025, Qyuns' 10th Anniversary Celebration was successfully held in Taizhou. All employees of Qyuns, along with representatives from research institutions, industry p...
2025-06-16 21:14
2454
Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announce...
2025-06-16 16:00
1649
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ -- Pierre Fabre Laboratories are pleased to announc...
2025-06-16 16:00
1857
The 4th Edition of AMSC Malaysia Returns in 2025: Uniting Global Leaders in Aesthetic Medicine, Dermatology, and Surgery
KUALA LUMPUR, Malaysia, June 16, 2025 /PRNewswire/ -- The Aesthetic Medicine &
Surgery Conference & Exhibition (AMSC)
2025-06-16 11:30
2108
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular Carcinoma...
2025-06-16 10:47
1837
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release caps...
2025-06-16 09:00
2460
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese
MD, proudly announces the successful completion of patient enrollment in the
TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to
evaluate the safety and efficacy of the MagicTouch
2025-06-13 19:59
2259
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 767762...
2025-06-12 21:17
1654
Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing
* 1st production of pharmaceutical grade egg and milk challenge meals * Product portfolio of challenge meals now includes peanut, milk and egg * Innovation pipeline includes development of 'Top 9' allergen products as well as a products suitable from 6 months DEESIDE, Wales, June 12, 2025 /P...
2025-06-12 19:06
1697
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱® ) was...
2025-06-11 11:34
2079
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy we...
2025-06-10 23:52
2877
Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in...
2025-06-10 09:00
1676
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 295 media titles]
2025-12-16 14:26
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 287 media titles]
2025-12-16 08:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
